Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating

BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of $8.00.

Julian Harrison’s rating is based on several promising developments in Aclaris Therapeutics’ pipeline, particularly their recent acquisition of rights to innovative anti-TSLP and anti-TSLP/IL4R monoclonal antibodies. The key asset, BSI-045B, has shown impressive potency in treating atopic dermatitis, boasting results that may potentially position it as a leading treatment option. Encouraging Phase 2a study outcomes, where BSI-045B demonstrated high efficacy rates without the need for topical corticosteroids, further amplify the drug’s potential in a market projected to grow significantly.
Additionally, the strategic acquisition includes the bispecific mAb BSI-502, which may offer additive efficacy by targeting multiple pathways, thereby addressing the complex nature of atopic dermatitis. This compound’s development plans, including expansion into other indications like COPD, combined with a solid financial position backed by substantial recent financing, provide a strong basis for the Buy rating. These factors, alongside a reduced discount rate which reflects increased confidence in the company’s prospects, underpin the optimistic outlook for Aclaris Therapeutics.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Aclaris Therapeutics (ACRS) Company Description:

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.